Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context: From General Health to Targeted Drug Safety

The domain saturday-reviewdrugtrials.com has historically provided evidence-based reporting on clinical research and drug safety, drawing on structured public data sources such as ClinicalTrials.gov, PubMed, and FDA databases. This heritage emphasizes accessible insights into therapeutic interventions and adverse event monitoring, serving both healthcare professionals and informed consumers. Within this framework, the domain has addressed broad topics in pharmacology, maintaining a neutral, data-driven perspective. Transitioning from this general health approach, a focused examination of specific drug-safety concerns becomes relevant. One such area involves the relationship between bisphosphonate medications, particularly Fosamax (alendronate), and the risk of osteonecrosis of the jaw (ONJ). While the legacy approach would situate this within a wider discussion of drug side effects, the present analysis narrows the lens to occupational exposure contexts, reframing the inquiry from a patient-centered safety profile to a workplace hazard assessment. This shift moves from general health literacy toward a targeted evaluation of exposure scenarios in professional settings, without delving into mechanistic claims or citing specific evidence.

Bridge Transition: From General Pharmacology to Specific Risk Assessment

Building on the domain's foundation in evidence-based drug safety, this article now focuses specifically on the scientific evidence connecting Fosamax (alendronate sodium) to osteonecrosis of the jaw (ONJ). The following sections examine the drug's mechanism, clinical presentation of ONJ, mechanistic pathways linking Fosamax to ONJ, risk factors, and the adequacy of warnings. This analysis is grounded in authoritative sources, including the FDA-approved prescribing information and peer-reviewed research, to provide a comprehensive overview of the causation question.

Fosamax: Mechanism and Approved Uses

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which reduces fracture risk but also alters normal bone remodeling. A recognized adverse effect associated with bisphosphonate therapy, including Fosamax, is osteonecrosis of the jaw (ONJ).

Clinical Presentation and Diagnosis of ONJ

ONJ is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves pain, swelling, infection, and delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis relies on clinical examination and imaging, with a focus on identifying necrotic bone that persists for more than eight weeks in the absence of prior radiation therapy.

Scientific Evidence Linking Fosamax to ONJ

Scientific evidence connects Fosamax to ONJ through several mechanistic pathways. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw. They inhibit osteoclast activity, which suppresses bone remodeling and repair. This suppression can lead to microdamage accumulation and reduced vascularity, making the jawbone more susceptible to necrosis, especially after invasive dental procedures. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies have examined the effects of bisphosphonate (alendronate) on jawbone in estrogen-deficient rats, revealing changes in tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings support the biological plausibility of Fosamax contributing to ONJ.

Timeline and Risk Factors for ONJ

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Clinical Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), which may complicate risk assessment. For affected patients, causation-related considerations involve evaluating the temporal relationship between Fosamax use and ONJ onset, excluding other causes such as radiation therapy or metastatic disease, and assessing the presence of known risk factors. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients should be informed about the importance of maintaining good oral hygiene and undergoing regular dental check-ups before and during bisphosphonate therapy. The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Summary of Causation Evidence

In summary, the scientific evidence supports a causal link between Fosamax and ONJ, mediated by bisphosphonate-induced suppression of bone remodeling. The risk is influenced by duration of exposure and presence of dental risk factors. While warnings exist in the prescribing information, the low incidence in clinical trials and variability in onset underscore the need for individualized risk-benefit assessment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Duration of bisphosphonate use may also increase risk.

How long after starting Fosamax can ONJ occur?

The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief after stopping, but some experienced recurrence upon rechallenge.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.